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Summary
C3H/HeN female mice were vaccinated with native Chlamydia muridarum
major outer membrane protein (MOMP), using Montanide+CpG or
Alum+CpG as adjuvants. Negative control groups were immunized with
ovalbumin (OVA) and the same adjuvants. As positive control, mice were
inoculated intranasally with live Chlamydia. Mice were challenged in the
ovarian bursa with 105 C. muridarum inclusion forming units. Six weeks
after the genital challenge the animals were caged with male mice and mon-
itored for pregnancy. Mice vaccinated with MOMP+Montanide+CpG devel-
oped high levels of C. muridarum-specific antibodies, with a high IgG2a/
IgG1 ratio and neutralizing titres. Animals immunized using Alum+CpG
had low antibody levels. Cellular immune responses were significantly
higher in mice vaccinated with MOMP and Montanide+CpG, but not with
Alum+CpG, when compared with negative controls. Following the genital
challenge, only 20% (4/20) of mice vaccinated with MOMP+CpG+Mon-
tanide had positive vaginal cultures whereas 100% (9/9) of mice immunized
with MOMP+CpG+Alum had positive cultures. Of the positive control ani-
mals inoculated with live Chlamydia only 15% (3/20) had positive vaginal
cultures. In contrast, 100% (20/20) of mice immunized with
OVA+CpG+Montanide, or minimal essential medium, had positive cul-
tures. Following mating, 80% (16/20) of mice vaccinated with
MOMP+CpG+Montanide, and 85% (17/20) of animals inoculated intrana-
sally with live C. muridarum carried embryos in both uterine horns. No
protection against infertility was observed in mice immunized with MOMP
and CpG+Alum or OVA. In conclusion, this is the first time that a subunit
vaccine has been shown to elicit a protective immune response in the highly
susceptible C3H/HeN strain of mice against an upper genital challenge.
Keywords: adjuvants; Chlamydia muridarum; immunization; major outer
membrane protein; mice.
Introduction
Throughout the world millions of individuals are infected
each year with Chlamydia trachomatis.1–3 The majority
of patients infected in the genitourinary tract remain
asymptomatic but others present with acute or chronic
symptomatology including cervicitis, urethritis, abdominal
pain, ectopic pregnancy and infertility.1,2,4 Ocular infec-
tions can also produce acute symptoms that can eventu-
ally result in trachoma.5,6 The reasons for this wide range
of presentations and outcomes have been attributed to
several pathogen- and host-related factors. For example,
Abbreviations: Cm, Chlamydia muridarum; EB, elementary bodies; IFN, interferon; IL, interleukin; i.n., intranasal; IFU, inclusion
forming units; MEM, minimum essential medium; MOMP, major outer membrane protein; MoPn, mouse pneumonitis; OVA,
ovalbumin; SI, stimulatory index; Th1, T helper type 1; VD, variable domains
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some isolates of C. trachomatis may be more virulent
than others.7–9 In addition, host factors play a significant
role in the outcome of the infection.10–13 For example,
genetic factors can affect susceptibility to infection and
the development of long-term sequelae.11–13 Specifically,
Kinnunen et al.11 found the DQA1*0102 and DQB1*0602
genotypes significantly more frequently in patients with
tubal factor infertility than in controls.
Chlamydia trachomatis isolates have been classified based
on the cross-reactivity among serum samples and mono-
clonal antibodies generated by inoculating mice with the
various serovars.14–16 Phylogenetic analysis of the nucleo-
tide sequence of the major outer membrane protein
(MOMP) supported the immunological classification of the
C. trachomatis.17,18 This protein has four variable domains
(VD), a trimeric b-barrel structure and porin func-
tion.17,19–21 The Chlamydia muridarummouse pneumonitis
(MoPn) isolate has been found to be able to infect mice of
different genetic backgrounds.22–24 However, susceptibility
to infection and development of long-term sequelae differ
significantly from strain to strain of mice, mimicking the
clinical presentations observed in humans.24–26
Screening for C. trachomatis and treating infected
patients with antibiotics does not appear to have yielded
the expected results. Several studies have shown that, fol-
lowing an initial decrease, there is a subsequent increase
in the prevalence of C. trachomatis infections.27,28 The
possibility that treating with antibiotics can result in a
decline of natural immunity has been considered as an
explanation for these findings.27,29,30 Hence, implementa-
tion of a vaccination programme has been proposed as a
necessary strategy for decreasing the burden of chlamydial
infections.31–38 The induction of an immune response by
a vaccine is under genetic control.39,40 Therefore, before
implementation in humans, it is necessary to test the effi-
cacy of vaccines in animals with various genetic back-
grounds.
Vaccines formulated with a native preparation of the
MoPn MOMP can effectively protect BALB/c (H-2d) and
C57BL/6 (H-2b) mice against chlamydial challenges.41–44
Here, we evaluated the efficacy of two vaccine formula-
tions with native MOMP to protect C3H/HeN mice. This
strain of mouse is exquisitely sensitive to chlamydial
infections and highly prone to develop long-term seque-
lae, e.g. infertility. Therefore, C3H/HeN mice may be rep-
resentative of humans susceptible to develop long-term
sequelae.24 In addition, C3H/HeN mount a weak immune
response to MOMP.45,46 Hence, engineering a vaccine to
protect C3H/HeN mice may pose unique challenges that
can provide valuable information for future implementa-
tion in humans. For these reasons and to improve the
chances of uncovering an efficacious vaccine formulation
we decided to compare two different types of combina-
tion adjuvants: one that includes adjuvants that favour a
T helper type 1 (Th1) -biased immune response
(CpG+Montanide), versus another adjuvant combination
that favours a Th2-biased response (CpG+Alum). Here,
for the first time, we have shown that a vaccine formu-
lated with MOMP can protect C3H/HeN mice against
genital challenge with Chlamydia.
Materials and methods
Stocks of Chlamydia
The C. muridarum [strain Nigg II; previously called Ch-
lamydia trachomatis mouse pneumonitis (MoPn) biovar]
was obtained from the American Type Culture Collection
(ATCC; Manassas, VA).22,47 Chlamydia muridarum was
grown in HeLa-229 cells with Eagle’s minimal essential
medium supplemented with 5% fetal calf serum.26 Ele-
mentary bodies (EB) were purified using Hypaque-76
(Nycomed Inc., Princeton, NJ) and stored at 70° in
02 M sucrose, 0020 M sodium phosphate (pH 72) and
0005 M glutamic acid.48
Purification of C. muridarum MOMP
Purification of native MOMP, directly from Chlamydia,
has been described elsewhere.41,42 Briefly, C. muridarum
was grown in McCoy monolayers, washed with PBS pH
74, centrifuged, and the pellet was treated with DNase.
After centrifugation the pellet was resuspended in 02 M
phosphate buffer pH 55, containing 01 M dithiothreitol,
and 0001 M each of EDTA and PMSF and extracted with
CHAPS (Anatrace, Inc., Maumee, OH), and subsequently
with Anzergent 3-14 (Z3-14; Anatrace, Inc.)49 The
MOMP was purified using a hydroxyapatite column.48
The purified MOMP was refolded in the presence of
reduced and oxidized glutathione. The preparation was
concentrated and fixed with glutaraldehyde, and 2 M gly-
cine was added to quench the reaction. The MOMP was
concentrated using polyethylene glycol and dialysed
against 002 M phosphate buffer pH 74, 015 M NaCl and
005% Z3-14 before immunization.
Animal immunization
Three-week-old female C3H/HeN (H-2k) mice were pur-
chased from Charles River Laboratory (Wilmington,
MA). Animals received a total of 10 lg of the MOMP, or
ovalbumin (OVA; Sigma-Aldrich, St Louis, MO) per
mouse per immunization.41,42 Animals were immunized
intramuscularly (5 lg/mouse) and subcutaneously (5
lg/mouse) with MOMP. Adjuvants used were: 10 lg of
CpG, [oligodeoxynucleotide-1826, (50-TCCATGACGTTC
CTGACGTT-30); Coley Pharmaceutical Group, Kanata,
ON], and Montanide ISA 720 (Seppic, Inc.; Fairfield, NJ)
at a 3 : 7 volume/volume ratio of MOMP+CpG to
Montanide, or 25 ll of Alum (Alhydrogel “85”; Superfos
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Biosector a/s; E.M. Sergeant Pulp & Chemical Co. Inc.,
Clifton, NJ).
Positive control C3H/HeN mice were immunized intra-
nasally (i.n.) with 101 inclusion forming units
(IFU)/mouse of C. muridarum in 40 ll of minimal essen-
tial medium (MEM).25,50 The number of IFU used for
this inoculation was ~10-fold lower than the 50% lethal
dose (LD50) for C3H/HeN mice.
50 A negative control
group was immunized i.n. with 40 ll of MEM. A fertility
control included animals that were not immunized, or
challenged, but were mated in parallel with the other
groups. All the experiments, except those involving
Alum+CpG as adjuvants, were repeated. All mouse proto-
cols were approved by the University of California, Irvine,
Animal Care and Use Committee.
Antibody detection
Following immunization, blood samples were collected
from the orbital plexus. Genital samples were collected by
washing the vagina twice with 20 ll of PBS. Chlamydia
muridarum-specific antibodies were measured in triplicate
using an ELISA.26 Flat-bottom 96-well plates were coated
with EB at a concentration of 10 lg/ml. A 1 : 1000 dilu-
tion of goat anti-mouse IgM, IgA, IgG (Cappel, Aurora,
OH) and a 1 : 100 dilution of goat anti-mouse IgG1,
IgG2a, IgG2b and IgG3 (Southern Biotechnology Associ-
ates, Birmingham, AL) was used to determine subclass or
isotype-specific antibody.
The ability of serum to neutralize in vitro the infectivity
of EB was determined as previously described.51 C. muri-
darum (104 IFU) were added to five-fold serial dilutions
of the serum made with 5% guinea-pig sera in Ca2+,
Mg2+-free PBS. After incubation at 37° for 45 min, the
mixture was used to inoculate HeLa-229 cells by centrifu-
gation. The cells were fixed with methanol at 30 hr after
infection, stained with a pool of monoclonal antibodies
prepared in our laboratory, and the number of IFU was
counted. Neutralization was defined as ≥ 50% inhibition
of the number of IFU using as a control the sera from
the animals inoculated with OVA.
For immunoblotting, EB were resolved in 10% tricine–
SDS–PAGE.52 A total of 20 µg of purified EB were loaded
on a 75-cm-wide slab gel. Following transfer to nitrocel-
lulose membranes, the non-specific sites were blocked
with BLOTTO [Bovine Lacto Transfer Technique Opti-
mizer: 5% (weight/volume) non-fat dried milk, 2 mM
CaCl2, and 50 mM Tris–HCl, pH 80], and the serum
samples were incubated overnight at 4°. Antibody binding
was detected using horseradish peroxidase-conjugated
goat anti-mouse antibody developed with 001% hydro-
gen peroxide and 4-chloro-1-naphthol. Monoclonal anti-
body MoPn-40 to MOMP was used as a control.
To detect antibodies elicited by vaccination to B-
cell-specific linear epitopes, overlapping 25-mers corre-
sponding to the mature MOMP amino acid sequence
were chemically synthesized (SynBioSci Corp., Livermore,
CA).53 Peptide 25 (p25) overlaps the N- and C-termini of
MOMP. The peptides were adsorbed onto high binding
affinity ELISA plates (10 lg/ml; 100 ll/well of a 96-well
plate) and the antibody binding was determined in tripli-
cates as described above using a 1 : 100 dilution of serum
and a 1/10 000 dilution of anti-mouse IgG.54
Lymphocyte proliferation assay
A T-cell lymphoproliferative assay was performed using
splenocytes as previously described.26 In brief, T-enriched
cells were counted and 105 cells were aliquoted as 200 ll
per well of a 96-well plate. UV-inactivated MoPn EB were
added at a concentration of 10 EB to 1 antigen-presenting
cells, which were prepared by irradiating splenocytes with
3300 rads. Negative control wells received medium alone
and positive controls wells received concanavalin A at a
concentration of 5 lg/ml. Cell proliferation was measured
by addition of 1 lCi of [3H]thymidine per well. The
mean count was obtained from triplicate cultures.
Measurement of cytokines
Levels of interferon-c (IFN-c) and interleukin-4 (IL-4)
were determined using commercial kits in supernatants
from splenic T cells stimulated as described above (BD
Pharmingen, San Diego, CA).26
Genital challenge
Four weeks after the last immunization, mice were anaes-
thetized with xylazine and ketamine, a lateral abdominal
incision was made, and 105 IFU of C. muridarum were
inoculated into the left ovarian bursa.23,26 The right ovar-
ian bursa was inoculated with mock-infected HeLa-229
cell extracts.
Vaginal cultures
To culture Chlamydia, vaginal swabs were collected at
weekly intervals following the genital challenge.26 Swabs
were vortexed in 200 ll of sugar phosphate glutamate
and two samples from each specimen (100 and 10 ll)
were inoculated into McCoy cells grown in 48-well plates.
The plates were centrifuged at 1000 g for 1 hr at room
temperature. Upon incubation at 37° for 30 hr they were
fixed and stained with a pool of monoclonal antibodies
to MoPn prepared in our laboratory.26
Fertility experiments
Six weeks after the genital challenge female mice were
caged with male breeder mice.26 Starting at 10 days post-
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mating female mice were weighed every 3 days. Animals
that gained weight were euthanized and the number of
embryos was counted. Mice that did not gain weight were
mated a second time with a different male mouse and the
outcome of the mating was evaluated as indicated above.
Statistics
The two-tailed unpaired Student t-test, the Fisher’s exact
test and the Mann–Whitney U-test were employed to
determine the significance of differences between the
groups using the STATVIEW software program on a Macin-
tosh computer (Apple Co, Cupertino, CA).
Results
Antibody titres in sera and vaginal washes following
vaccination
Following immunization serum samples were tested by an
ELISA for the presence of C. muridarum-specific anti-
body. The antibody titres the day before the genital chal-
lenge, using EB as the antigen, are shown in Table 1.
High Chlamydia-specific antibody titres in serum were
observed in the C3H/HeN animals vaccinated with
MOMP+CpG+Montanide. The titre of total IgG in this
group of mice was 51 200. In the same group of animals
the titre of IgG2a was 51 200 and of IgG1 was 6400. The
high ratio (8) of IgG2a/IgG1 is indicative of a Th1
response. In the group of animals immunized with
MOMP+CpG+Alum the total IgG titre was 1600 and the
IgG2a/IgG1 ratio was 2 (1600/800) consistent with a bal-
anced Th1/Th2 response. Mice immunized i.n. with C.
muridarum EB had an IgG serum titre of 12 800. This
control group had high levels of IgG2a when compared
with those of IgG1 (12 800/1600; ratio = 8), which was
indicative of a strong Th1 response. Control groups
immunized with OVA+CpG+Montanide, OVA+CpG+A-
lum, or MEM had no detectable antibody to Chlamydia.
The neutralizing antibody titre in serum in the group of
mice vaccinated with MOMP+CpG+Montanide was 6250.
In contrast, in mice immunized with MOMP+CpG+Alum
the neutralizing titre was 250 (Table 1). In the control group
inoculated i.n. with MoPn EB the neutralizing titre was
1250. Sera from mice immunized with OVA+CpG+Mon-
tanide, OVA+CpG+Alum, or MEM, served as the respective
controls for the above three groups.
The titres of C. muridarum-specific IgA and IgG anti-
bodies in vaginal washes in mice vaccinated with
MOMP+CpG+Montanide were 20 and 320, respectively.
In the group vaccinated with MOMP+CpG+Alum the
titre of IgA in the vaginal washes was 10 and of IgG was
20. High levels of IgA, titre 160, were detected in the
vaginal washes of the mice inoculated i.n. with live EB
whereas the IgG titre in this group was 40. No Chlamy-
dia-specific antibodies were detected in the vaginal washes
of the control groups immunized with OVA or MEM.
Characterization of the antibody response with
immunoblots and synthetic peptides
An immunoblot, using serum collected the day before the
genital challenge, is shown in Fig. 1. As expected, mice vac-
cinated with MOMP+CpG+Montanide, or MOMP+Cp-
G+Alum, developed antibody only against MOMP.
Animals immunized i.n. with EB had antibody predomi-
nantly to two bands of a high molecular weight
(> 100 000), the 60 000 MW cysteine-rich protein, the
60 000 MW heat-shock protein, MOMP, a 23 000 MW
protein and lipopolysaccharide. Control mice immunized
with OVA, or MEM, had no antibody reactive with any of
the chlamydial components.
To determine the linear epitopes recognized by the
antibody from mice immunized with MOMP, or EB,
serum samples were tested against synthetic 25mer pep-
tides of MOMP. As shown in Fig. 2, IgG from mice vac-
cinated with MOMP+CpG+Montanide bound to the four
VDs of MOMP. Lower levels of antibody were detected
Table 1. Antibody titres the day before the genital challenge
Antigen Adjuvant
Chlamydia muridarum-specific ELISA antibody titre
Serum neutralizing titre
Serum
Vaginal
wash
IgM IgG IgG1 IgG2a IgG2b IgG3 IgA IgG IgA
MOMP CpG+Montanide 100 51 200 6400 51 200 51 200 6400 1600 320 20 6250
Ovalbumin CpG+Montanide <100 <100 <100 <100 <100 <100 <100 <10 <10 <50
MOMP CpG+Alum <100 1600 800 1600 1600 800 200 20 10 250
Ovalbumin CpG+Alum <100 <100 <100 <100 <100 <100 <100 <10 <10 <50
Cm EB <100 12 800 1600 12 800 12 800 3200 1600 40 160 1250
MEM <100 <100 <100 <100 <100 <100 <100 <10 <10 <50
EB, elementary body; MEM, minimal essential medium; MOMP, major outer membrane protein.
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against VD2, VD3 and VD4 and no antibodies recognized
VD1, in sera from mice vaccinated with MOMP+CpG+A-
lum. Sera from mice vaccinated with MOMP+CpG+Mon-
tanide or MOMP+CpG+Alum recognized peptides
outside the VD whereas sera from animals immunized
with EB only recognized epitopes in the VD.
Determination of cell-mediated immune responses
T lymphocytes, stimulated with EB, from animals vacci-
nated with MOMP+CpG+Montanide showed an increase
in their lymphoproliferative responses in comparison with
the corresponding OVA control group [stimulation index
(SI) 94 versus 19; P < 005; Table 2]. No increase in the
lymphoproliferative response was observed in the mice
immunized with MOMP+CpG+Alum (SI 20 versus 24;
P > 005). Control C3H/HeN mice inoculated i.n. with
live C. muridarum showed a significant lymphoprolifera-
tive response to C. muridarum EB when compared with
the MEM group (SI 800 versus 24; P < 005). The lym-
phoproliferative responses to concanavalin A and media,
used as positive and negative controls, respectively, were
equivalent among all the groups.
The levels of IFN-c from supernatants of splenocytes
stimulated with C. muridarum EB in the mice vaccinated
with MOMP+CpG+Montanide were elevated when com-
pared with the respective OVA-immunized control groups
(6682 versus 4792; P < 005; Table 2). No increase in the
levels of IFN-c was observed in the group immunized with
MOMP+CpG+Alum (2308 versus 2272; P > 005). The
animals immunized i.n. with live Chlamydia had signifi-
cantly higher levels of IFN-c in the supernatants when
compared with the control group immunized with MEM
(72 149 versus 1883; P < 005). The levels of IL-4 were
below the level of detection in all the groups (< 08 pg/ml).
Vaginal cultures
Four weeks after the last systemic immunization, mice were
challenged in the left ovarian bursa with 105 IFU of
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Figure 1. Immunoblot of Chlamydia muridarum elementary bodies
(EB) probed with serum samples collected from immunized C3H/
HeN mice. Lane 1, molecular weight standards; lane 2, serum sample
diluted 1 : 100 collected before immunization. Serum samples col-
lected the day before the genital challenge from mice immunized
with the following: lane 3, major outer membrane protein
(MOMP)+CpG+Montanide (serum dilution 1 : 40 000); lane 4,
MOMP+CpG+Alum (serum dilution 1 : 10 000); lane 5, C. muri-
darum EB (serum dilution 1 : 100); lane 6, control monoclonal anti-
body MoPn-40 to MOMP (dilution 1 : 5).
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Figure 2. Mapping of antibodies to linear epitopes of major outer
membrane protein (MOMP) using synthetic peptides. Overlapping
25mer peptides corresponding to the Chlamydia muridarum MOMP
were incubated with serum samples from mice immunized with
MOMP+CpG+Montanide (top), MOMP+CpG+Alum (middle) or
live C. muridarum elementary bodies (EB) (bottom).
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C. muridarum and the course of the infection was assessed
over a period of 6 weeks using vaginal cultures. As shown
in Fig. 3a, Chlamydia was recovered from the vaginal cul-
tures in only 20% (4/20) of the mice vaccinated with
MOMP+CpG+Montanide. Similarly, only 15% (3/20) of
the mice immunized i.n. with live EB had positive vaginal
cultures over the 6 weeks of observation. No statistically
significant difference was found in the number of mice
with positive vaginal cultures between these two groups
(P > 005). All the animals (20/20) immunized with
OVA+CpG+Montanide and the group of controls immu-
nized with MEM had positive vaginal cultures. In addition,
no statistically significant differences in the total or per
week, number of IFU recovered, or in the length of vaginal
shedding, were observed between the group vaccinated
with MOMP+CpG+Montanide and the mice immunized
i.n. with live EB (P > 005) (Figs 3b and 4). The number
of Chlamydia IFU recovered during the first 3 weeks
after the challenge was significantly lower in the
MOMP+CpG+Montanide-vaccinated animals than in the
corresponding OVA+CpG+Montanide-immunized control
group (P < 005). All animals vaccinated with MOMP+Cp-
G+Alum, and the controls immunized with OVA+CpG+A-
lum, had positive vaginal cultures. Therefore, there was no
significant statistical difference between the two groups
(P > 005). Also, no differences in the number of IFU
recovered, or in the length of the vaginal shedding, were
noted between these two groups (P > 005).
Fertility studies
Six weeks after the genital challenge, female mice
were housed in the same cage with male mice and the
pregnancy outcome was followed over a course of
two mating cycles (Fig. 5). Mice vaccinated with
MOMP+CpG+Montanide, controls immunized i.n. with
EB, and the fertility control group all had equivalent fer-
tility rates in the left uterine horn: 80% (16/20), 85%
(17/20) and 100% (18/18), respectively (P > 005). No
protection against infertility was observed in mice vacci-
nated with MOMP+CpG+Alum when compared with
the animals immunized with OVA+CpG+Alum (11%
versus 0%; P > 005). The controls, immunized with
OVA+CpG+Montanide, and the group inoculated with
MEM had fertility rates of 5% (1/20) and 15% (3/20),
respectively (P < 005).
The number of embryos in the challenged left uterine
horn, and the total number of embryos per mouse, were
also equivalent for the MOMP+CpG+Montanide vacci-
nated group, the animals immunized i.n. with live Ch-
lamydia and the fertility control mice. For example, in
the group vaccinated with MOMP+CpG+Montanide,
mice immunized i.n. with EB and in the fertility control
group, the mean numbers of embryos in the left uterine
horn were 28, 33 and 33, respectively (P > 005). Simi-
larly, the means of the total number of embryos in the
three groups 56, 71 and 78, respectively, were not
significantly different (P > 005). In contrast, the total
number of embryos in mice vaccinated with MOMP+Cp-
G+Alum was not significantly different from the number
of embryos in the animals immunized with OVA+Cp-
G+Alum (14 and 09; P > 005). The groups immunized
with OVA+CpG+Montanide, or with MEM, had signifi-
cantly fewer embryos in both uterine horns, 10 and 21,
respectively, than the group vaccinated i.n. with EB
(P < 005).
Table 2. T-cell responses the day before the genital challenge1
Antigen Adjuvant
T-cell proliferation responses to: In vitro cytokine production
EB2 Con A3 Medium IFN-c (pg/ml) IL-4 (pg/ml)
CPM x103 SI4 CPM x103 SI4 CPM x103 SI4 EB2 Con A3 EB2 Con A3
MOMP CpG+Montanide 13  075 945,6 323  92 223 02  01 1 6682  4025,6 77 892  6850 <08 <08
Ovalbumin CpG+Montanide 08  07 19 290  77 80 04  02 1 4792  612 80 668  4650 <08 <08
MOMP CpG+Alum 03  01 20 339  143 211 02  01 1 2308  724 76 805  2987 <08 <08
Ovalbumin CpG+Alum 05  02 24 209  57 99 02  01 1 2272  498 80 341  1687 <08 <08
Cm EB 69  285 8005 366  101 391 01  002 1 72 149  13 9105 71 820  3964 <08 <08
MEM 03  01 24 433  153 309 01  01 1 1883  791 70 052  3863 <08 <08
ConA, concanavalin A; EB, elementary body; IFN-c, interferon-c; IL-4, interleukin-4; MEM, minimal essential medium; MOMP, major outer
membrane protein.
1Results are means for triplicate cultures (1 SD). Data correspond to one of the experiments representative of duplicate separate experiments.
2UV-inactivated Chlamydia muridarum EB were added at a 10 : 1 ratio to the antigen-presenting cells.
3Concanavalin A was added at a concentration of 5 µg/ml.
4SI = stimulation index (CPM of EB stimulated/CPM of medium stimulated).
5P < 005 by the Student’s t-test, compared with the corresponding MEM-immunized control group.
6P < 005 by the Student’s t-test, compared with the corresponding ovalbumin-immunized control group.
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Discussion
In this study we have shown that, a subunit vaccine for-
mulated with the native MOMP, and adjuvants that
favour a Th1 response, can induce a protective immune
response in C3H/HeN (H-2k) female mice against a
C. muridarum genital infection. Mice vaccinated with
MOMP had a significant decrease in vaginal shedding
that was similar to that observed in the control animals
immunized with live EB. In addition, the fertility rates of
MOMP vaccinated animals were equivalent to the fertility
rates of the EB-immunized controls. These findings, in
conjunction with previous results in BALB/c and C57BL/
6 mice, provide support for the feasibility of engineering
a subunit vaccine against C. trachomatis infections that
can be effective in populations with different genetic
backgrounds.41,43 Although others have reported protec-
tion against a vaginal challenge, to the best of our knowl-
edge, only a subunit vaccine formulated with MOMP,
and adjuvants that favour a Th1 response, have been
shown to protect three strains of mice, with different
genetic backgrounds, against an upper genital challenge
with Chlamydia.41,43,44,55,56
The very high degree of polymorphism of the MHC
molecules in the human population presents a difficult
obstacle to overcome for the implementation of vaccines.
Data from human studies and experimental models have
shown that the ability of a vaccine to elicit a protective
immune response is dependent, among other factors, on
the genetic makeup of the individual.57–59 Addressing this
issue, using subunit vaccines, is particularly important for
pathogens such as C. trachomatis that are widespread
throughout the world and affect individuals with very
diverse genetic backgrounds. In subunit vaccines the
number of protective epitopes is limited and, as a result,
certain individuals may lack the MHC determinants
needed to recognize the restricted number of epitopes.
Furthermore, when using vaccines with live organisms,
the in vivo replication of the attenuated pathogen
increases the antigen load. In contrast, in the case of sub-
unit vaccines, not delivered using replicating vectors, the
amount of antigen is limited to the quantity inoculated at
the time of immunization.
Vaccines for C. trachomatis infections were first tested
to protect against trachoma. Immunization trials in
humans and non-human primates provided encouraging
results.2,6,32,60 Vaccines with the whole organism elicited
protection although it was limited to a few years. Further-
more, the protection was, at least in part, serovar, or sub-
group, specific. Individuals vaccinated with one of the
serovars were protected against a subsequent exposure to
the same, or related serovar, but not against one of the
distantly related serovars.2,6,32,60 In addition, in certain
individuals, exposure to C. trachomatis following vaccina-
tion resulted in a hypersensitivity reaction.60–63 It is con-
sidered that the hypersensitivity reaction occurs as a
result of an immune response to one of the antigenic
components present in Chlamydia. Although still under
investigation, the 60 000 MW heat-shock protein, has
been considered a candidate for this hypersensitivity reac-
tion.64–70 As a result of the concerns with the hypersensi-
tivity reaction current efforts have been focused on
producing a subunit vaccine.
Using animal models, various components of both the
humoral and the cell-mediated immune responses have
been shown to play a role in protection against C. tra-
chomatis infections.31,71–73 Passive immunization of mice
with monoclonal IgA and IgG subclasses, to conforma-
tional epitopes of the C. muridarum MOMP, resulted in
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Figure 3. Percentage of mice with positive vaginal cultures. (a) Total
percentage of mice that had positive vaginal cultures over the 6-week
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lenged with 105 inclusion forming units (IFU) of Chlamydia muri-
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sponding ovalbumin or minimal essential medium (MEM) -
immunized control groups.
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significant protection against vaginal and respiratory
challenges.74,75 Work with C57BL/6 knockout mice indi-
cates that CD4+ T cells are required for protection,
whereas CD8+ T cells probably play a secondary role.
Using C57BL/6 knockout mice, B cells and/or antibody
have been shown to have a role in protection against a
challenge with C. muridarum.43,71,72 Protection against
MoPn seems to be mediated by Th1 cells as C57BL/6 ani-
mals deficient in IL-12, IFN-c, or the IFN-c receptor,
cannot control an infection.31,71,72 However, for vaccine-
induced protection, as in the case of re-infection, anti-
bodies are also critical because they are as protective as
CD4+ T cells.43,73,76,77 The very high level of protection
against infection and disease shown in these experiments
supports previous findings that linked antibodies to pro-
tection against upper genital pathology.41,75,78,79
Structural and immunological characterization of MOMP
suggests that this protein mediated the serovar specificity of
the protection observed in the trachoma vaccination tri-
als.6,18,80,81 Taylor et al.82 immunized monkeys with MOMP
and observed no protection against an ocular challenge.
Other investigators using preparations of MOMP obtained
similar disappointing results.83–85 Based on these results it
was proposed that conformational epitopes present in
MOMP might be required for protection.31,33,86,87 Support
for this possibility was provided when, vaccines formulated
with outer membrane complexes of Chlamydia, or with
dendritic cells pulsed ex vivo with non-viable EB, were
shown to induce significant protection against a genital
challenge.41,42,84,86,88,89
In these experiments C3H/HeN mice immunized with
native MOMP, and adjuvants that favour a Th2 response,
were not protected against a genital challenge. In contrast,
the immune response elicited in C3H/HeN mice by vacci-
nation with the MoPn MOMP, and the Th1 adjuvant
combination CpG+Montanide, was as protective as that
resulting from intranasal inoculation with live Chlamydia.
Therefore, as for BALB/c and C57BL/6 mice, a Th1
immune response appears to be necessary for protecting
C3H/HeN mice against a genital challenge.44,72,73 Interest-
ingly, the immune response of the C3H/HeN mice to this
vaccination protocol is different from that observed in
BALB/c and C57BL/6 mice. Overall, the C3H/HeN mice
vaccinated with MOMP+CpG+Montanide had a strong
humoral immune response and a weak cell-mediated
immune response, whereas in BALB/c, or C57BL/6 mice
the same immunization elicited more robust responses
from both arms of the immune system.41,42,55,73 A weaker
protection in C3H/HeNCrl (H2k), in comparison to
BALB/c (H2d) and C57BL/6 (H2b) mice, was also recently
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Figure 4. Number of Chlamydia muridarum
inclusion forming units (IFU) detected in the
vaginal cultures. Vaccinated mice were chal-
lenged with 105 IFU of C. muridarum in the
left ovarian bursa, vaginal cultures were col-
lected weekly and the number of IFU present
in each culture was determined. aP < 005 by
the Mann–Whitney U-test compared with the
corresponding ovalbumin or minimal essential
medium (MEM) -immunized control groups.
ª 2015 John Wiley & Sons Ltd, Immunology, 146, 432–443 439
Chlamydia vaccine-induced protection in C3H/HeN mice
reported by Yu et al.90 in animals immunized with
combinations of polymorphic membrane proteins, recom-
binant MOMP and Th1 adjuvants. In these experiments
they only obtained protection against vaginal shedding
but not against hydrosalpinx formation.
To further dissect the differences between the responses
of various strains of mice, we determined the linear epi-
topes of MOMP recognized by serum antibodies from the
immunized mice. With this method we have previously
shown that antibodies from BALB/c mice immunized
with EB, or with MOMP, recognize all four VD of
MOMP.26,55 In contrast, only antibodies from C3H/HeN
vaccinated with MOMP recognized all VD whereas serum
from mice immunized with EB had only a very weak
response to the two dominant domains VD1 and VD4.
Probably, animals immunized with EB, developed anti-
bodies mainly to non-linear epitopes of MOMP, or to
antigens other than MOMP, whereas mice immunized
with MOMP had more robust humoral responses to lin-
ear epitopes of MOMP.
As a measure of the cellular immune response we used
a lymphoproliferative assay using T-cells purified from
the spleen. T cells, stimulated with EB, from EB- or
MOMP-immunized BALB/c and C57BL/6 mice, mounted
robust lymphoproliferative responses and high IFN-c
levels were measured in the supernatants.41,43 In contrast,
in C3H/HeN mice weaker lymphoproliferative responses
were observed in animals immunized with MOMP. How-
ever, a strong proliferative response, and high levels of
IFN-c in the supernatants, were demonstrated in mice
immunized with live EB. Therefore, C3H/HeN mice do
not produce very strong T-cell immune responses to
MOMP. In this respect, Westbay et al.,46 immunized
C3H/HeJ (H-2K), BALB/c (H-2d) and BALB.K (H-2k)
with recombinant MOMP, using Alum as the adjuvant,
and reported that, in contrast with the H-2d mice, the H-
2k strains of mice were deficient in MOMP-specific helper
T cells and had low Chlamydia-specific antibody levels.
Based on these findings the authors questioned whether a
vaccine formulated with MOMP could protect C3H/HeN
(H-2K) mice. Similarly, Motin et al.45 showed that
C3H/HeBkI (H-2k) mice had weaker lymphoproliferative
responses to a peptide from a VD of MOMP than
C57BL/6 animals. In spite of these observations, our
results clearly show that C3H/HeN (H-2K) mice can be
protected with a vaccine formulated with MOMP and
Th1 adjuvants.
Until recently it was thought that protection induced
by non-linear, or conformational, epitopes was dependent
on antibody. In the last few years it has become evident
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Figure 5. Seven weeks after the genital chal-
lenge female mice were caged with male bree-
der mice and their pregnancy status was
followed in fertility studies. Mice that became
pregnant were euthanized and the number of
embryos was counted in each uterine horn. (a,
c, e) Percentage fertile mice in the left, right
and both uterine horns, respectively; (b, d, f)
number of embryos in the left, right and both
uterine horns, respectively. aP < 005 by the
Fisher’s Exact test when compared with the
corresponding ovalbumin or minimal essential
medium (MEM) -immunized negative control
groups. bP > 005 by the Fisher’s Exact test
when compared with the fertility control
group. cP < 005 by the Mann–Whitney U-test
when compared with the corresponding oval-
bumin- or MEM-immunized negative control
groups. dP > 005 by the Mann–Whitney U-
test when compared with the positive control
elementary body (EB) -immunized group.
eP > 005 by the Mann–Whitney U-test when
compared with the fertility control group.
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that T cells can also recognize non-linear epitopes. For
example, Musson et al.91 showed that the degree of anti-
gen processing was dependent on the localization of the
epitopes of the Yersinia pestis Caf1 protein. Epitopes
located in the globular domains were presented by newly
synthesized MHC class II, after low pH-dependent lysoso-
mal processing, whereas epitopes from a flexible strand of
the protein were presented by mature MHC class II, inde-
pendent of low pH, and did not require proteolytic pro-
cessing. These findings have now been confirmed by
other investigators, who have demonstrated that the exci-
sion and splicing reactions of amino acids occurred in
the proteasome.92 In the case of MOMP, conformational
epitopes appear to play a significant role in the induction
of protective immune responses.31,42,75 It is therefore pos-
sible that amino acid sequences from non-contiguous
regions of the molecule may form new T-cell epitopes via
post-translation transpeptidation in the host proteasome.
As a result, both the protective humoral and the cell-me-
diated immune responses could, at least in part, be medi-
ated by epitopes that are conformation dependent.
A limitation of this study is that we used the intrabur-
sal challenge model developed by Swenson and Schach-
ter.23 The main shortcoming of this model is that it does
not parallel the natural route of infection. However, by
directly challenging the site we are interested in protect-
ing, it may provide a more stringent proof of the efficacy
of the vaccine.73 The feasibility of determining the ability
of Chlamydia to disseminate from one uterine horn to
the other is another advantage of using the intrabursal
versus the vaginal challenge. With the intravaginal model,
to increase the susceptibility to infection and facilitate the
development of infertility, the mice are treated with pro-
gesterone before they are challenged. Progesterone has
strong immunomodulatory effects in mice and humans
and induces a shift from Th1 to a Th2 response.93–95 A
Th1 response is considered to be necessary for protection
against a chlamydial infection. Hence, treating animals
with progesterone before the challenge can mask the pro-
tective effects of a vaccine.93,94
In conclusion, vaccination of C3H/HeN mice with a
native preparation of MOMP and adjuvants that favour a
Th1 response elicits protective immune responses against
a genital challenge as effective as that induced by immu-
nization with live organisms. The results of the analyses
of the immune responses in C3H/HeN, BALB/c and
C57BL/6 mice indicate that different strains process puri-
fied MOMP differently from the one present in EB. A
more detailed analysis is required to better understand
the differences in the immune responses to vaccination
between the strains, as this may help to improve the for-
mulation of a vaccine for humans. Our results emphasize
the need to test vaccination protocols in animals with dif-
ferent genetic backgrounds and stress the difficulties
encountered in establishing immunological parameters
that correlate with protection against chlamydial infec-
tions.
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